These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19519271)

  • 1. Atomoxetine hydrochloride-associated transient psychosis in an adolescent with attention-deficit/hyperactivity disorder and mild mental retardation.
    Tang CS; Chou WJ; Cheng AT
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):319-20. PubMed ID: 19519271
    [No Abstract]   [Full Text] [Related]  

  • 2. Atomoxetine-induced vocal tics in a patient with schizophrenia.
    Raveendranathan D; Rao MG; Varambally S; Venkatasubramanian G; Gangadhar BN
    J Neuropsychiatry Clin Neurosci; 2012; 24(4):E45-6. PubMed ID: 23224483
    [No Abstract]   [Full Text] [Related]  

  • 3. Atomoxetine-induced mydriasis.
    Alhatem FJ; Decker DH
    J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):539-41. PubMed ID: 18928421
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent camptocormia associated with atomoxetine in a child with attention-deficit/hyperactivity disorder.
    Bhattacharya A; Praharaj SK; Sinha VK
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):596-7. PubMed ID: 25469421
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute urinary retention associated with atomoxetine use.
    Desarkar P; Sinha VK
    Aust N Z J Psychiatry; 2006 Oct; 40(10):936. PubMed ID: 16959021
    [No Abstract]   [Full Text] [Related]  

  • 6. A case of severe akathisia with atomoxetine.
    Baweja R; Petrovic-Dovat L
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):426-7. PubMed ID: 23952192
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
    Gökçen C; Kutuk MO; Coşkun Ş
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):428-30. PubMed ID: 23952193
    [No Abstract]   [Full Text] [Related]  

  • 8. Idiosyncratic liver failure probably associated with atomoxetine: a case report.
    Erdogan A; Ozcay F; Piskin E; Karaman MG; Bilezikci B; Calik M; Tekin I; Haberal M
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):295-7. PubMed ID: 21663435
    [No Abstract]   [Full Text] [Related]  

  • 9. Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit/hyperactivity disorder and tic disorder.
    Liu CC; Lan CC; Chen YS
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):466-7. PubMed ID: 25020072
    [No Abstract]   [Full Text] [Related]  

  • 10. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine-induced mania-like symptoms in an adolescent patient.
    Bahali K; Uneri OS; Ipek H
    Actas Esp Psiquiatr; 2013; 41(2):137-8. PubMed ID: 23592075
    [No Abstract]   [Full Text] [Related]  

  • 12. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine-induced hypomania-like symptoms in a preadolescent patient.
    Guney E; Uneri OS
    J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):530-1. PubMed ID: 24494808
    [No Abstract]   [Full Text] [Related]  

  • 15. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
    McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; White KG; Brady KT
    Am J Addict; 2010; 19(6):481-9. PubMed ID: 20958842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The treatment of attention deficit hyperactivity disorder with comorbid tic hyperkinesis].
    Chutko LS; Surushkina SIu; Nikishena IS; Iakovenko EA; Lapshina OV; Anisimova TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(2):66-8. PubMed ID: 18646384
    [No Abstract]   [Full Text] [Related]  

  • 17. [Atomoxetine (strattera) in the treatment of attention deficit hyperactivity syndrome].
    Ershova A
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):87-91. PubMed ID: 19097312
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.
    Dell'Agnello G; Zuddas A; Masi G; Curatolo P; Besana D; Rossi A
    CNS Drugs; 2009 Sep; 23(9):739-53. PubMed ID: 19689165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buspirone use in the treatment of atomoxetine-induced bruxism.
    Yüce M; Karabekiroğlu K; Say GN; Müjdeci M; Oran M
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):634-5. PubMed ID: 24206098
    [No Abstract]   [Full Text] [Related]  

  • 20. Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder?
    Banerjee S; Ayyash HF
    Arch Dis Child Educ Pract Ed; 2008 Aug; 93(4):131-2. PubMed ID: 18644903
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.